Literature DB >> 29655935

Establishing the diagnosis of chronic colonization with Pseudomonas aeruginosa of cystic fibrosis patients: Comparison of the European consensus criteria with genotyping of P. aeruginosa isolates.

Leander Jonckheere1, Petra Schelstraete2, Leen Van Simaey3, Eva Van Braeckel4, Julie Willekens5, Sabine Van Daele6, Frans De Baets7, Mario Vaneechoutte8.   

Abstract

After antibiotic eradication treatment for a first ever Pseudomonas aeruginosa isolation, the European consensus criteria (ECC) are widely used to assess colonization status with P. aeruginosa in CF-patients. We evaluated to what extent genotyping (GT) of subsequent P. aeruginosa isolates could predict/assess chronic colonization (CC), in comparison with the ECC.
METHODS: Over a 14-year period, sputa were cultured from 80 CF-patients (age range: 2-51 years), from a first ever isolation of P. aeruginosa onwards. Patients with a positive culture for P. aeruginosa received antibiotic eradication treatment. For the 40 patients for whom three or more P. aeruginosa isolates were available, these isolates were genotyped.
RESULTS: According to the ECC, 27 out of the 40 patients (67.5%) became CC during the study period (ECC-positive patients). Genotyping confirmed persistence of the same genotype for 25 of these ECC-positive patients. Genotyping indicated persistence of the same genotype for at least two subsequent isolates for 5 out of 13 ECC-negative patients. Culture-positivity characteristics of the 27 ECC-positive patients corresponded well to those of the 30 GT-positive patients, with an overall higher number of positive cultures as well as a shorter interval in between first and second isolate compared to ECC-negative and GT-negative patients. Genotyping indicated persistence of the same genotype on average 9.3 months earlier than CC according to the ECC (P < 0.01).
CONCLUSIONS: Genotyping of P. aeruginosa isolates confirmed CC for 25 out of 27 ECC-positive patients (92.6% specificity) and predicted CC 9.3 months earlier than the ECC.
Copyright © 2018 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; European consensus criteria (ECC); Genotyping (GT); McRAPD; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2018        PMID: 29655935     DOI: 10.1016/j.jcf.2018.03.004

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  5 in total

1.  Antibacterial Activity of a Lytic Enzyme Encoded by Pseudomonas aeruginosa Double Stranded RNA Bacteriophage phiYY.

Authors:  Yuhui Yang; Shuai Le; Wei Shen; Qian Chen; Youying Huang; Shuguang Lu; Yinling Tan; Ming Li; Fuquan Hu; Yang Li
Journal:  Front Microbiol       Date:  2018-08-03       Impact factor: 5.640

Review 2.  Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation.

Authors:  Meraj A Khan; Zubair Sabz Ali; Neil Sweezey; Hartmut Grasemann; Nades Palaniyar
Journal:  Genes (Basel)       Date:  2019-02-26       Impact factor: 4.096

3.  Commensal Bacteria in the Cystic Fibrosis Airway Microbiome Reduce P. aeruginosa Induced Inflammation.

Authors:  Andrew Tony-Odigie; Leonie Wilke; Sébastien Boutin; Alexander H Dalpke; Buqing Yi
Journal:  Front Cell Infect Microbiol       Date:  2022-01-31       Impact factor: 5.293

4.  "Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Authors:  Peter H Gilligan; Damian G Downey; J Stuart Elborn; Patrick A Flume; Sebastian Funk; Deirdre Gilpin; Timothy J Kidd; John McCaughan; B Cherie Millar; Philip G Murphy; Jacqueline C Rendall; Michael M Tunney; John E Moore
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

5.  Development of a Bacteriophage Cocktail to Constrain the Emergence of Phage-Resistant Pseudomonas aeruginosa.

Authors:  Yuhui Yang; Wei Shen; Qiu Zhong; Qian Chen; Xuesong He; Jonathon L Baker; Kun Xiong; Xiaoling Jin; Jing Wang; Fuquan Hu; Shuai Le
Journal:  Front Microbiol       Date:  2020-03-04       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.